Aliskiren Flops as Add-On Therapy in Systolic HFAliskiren Flops as Add-On Therapy in Systolic HF

Signals of biomarker improvement and a differential clinical effect by diabetes status are highlights of the trial, but not efficacy for the primary end point: six-month CV death or heart-failure rehospitalization. Heartwire
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news

Related Links:

This exploratory analysis of a randomized trial examined the effect of dapagliflozin on a composite of worsening heart failure or cardiovascular death on individuals with heart failure with reduced ejection fraction with and without diabetes.
Source: JAMA - Journal of the American Medical Association - Category: General Medicine Source Type: research
This study evaluated whether A1C influences a composite outcome of either HF hospitalization or CV death differently along the spectrum of LVEF.Methods and resultsWe assessed the relationships of baseline A1C and LVEF with a composite outcome of either CV death or HF hospitalization in the 4091 patients with type 2 diabetes and a recent acute coronary syndrome enrolled in the ELIXA trial who had available LVEF. We assessed for interaction between A1C and LVEF as continuous variables with respect to this outcome. During a median follow ‐up of 25.7 months, 343 patients (8.4%) had HF hospitalization or died of CV ca...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
AbstractAimsNon ‐cardiac comorbidities are highly prevalent in patients with heart failure (HF). Our objective was to define the association between non‐cardiac comorbidity burden and clinical outcomes, costs of care, and length of stay within a large randomized trial of acute HF patients.Methods and resultsPatients with complete medical history for the following comorbidities were included: diabetes mellitus, chronic obstructive pulmonary disease, chronic liver disease, history of cancer within the last 5  years, chronic renal disease (baseline serum creatinine>3.0  mg/mL), current smoking, alcohol ab...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
This study included 1962 patients who underwent transesophageal echocardiographic examination (TEE) prior to cardioversion or ablation in the years 2014-2018 in three cardiac centers. RESULTS: More than a quarter of AF patients had decreased eGFR (
Source: Cardiology Journal - Category: Cardiology Authors: Tags: Cardiol J Source Type: research
Higher intake of isoflavones and tofu associated with moderately lower risk of developing CHD especially for some women Related items fromOnMedica Taxing unhealthy products may help tackle chronic diseases Most supplements offer no real benefit, some might increase risks Plant-based diet linked to lower risk of heart failure Vitamin D supplements do not confer cardiovascular protection Fish oils do not prevent heart attack or strokes with diabetes
Source: OnMedica Latest News - Category: UK Health Source Type: news
Left ventricular ejection fraction (LVEF) trajectories and functional recovery with current heart failure (HF) management is increasingly recognized. Type 2 diabetes mellitus (T2D) leads to a worse prognosis i...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Original investigation Source Type: research
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Myocardial contractile dysfunction in diabetic cardiomyocytes is a significant promoter of heart failure. Herein, we investigated the effect of icariin, a flavonoid monomer isolated from Epimedium, on diabetic cardiomyopathy (DCM) and explored the mechanisms underlying its unique pharmacological cardioprotective functions. High glucose (HG) conditions were simulated in vitro using cardiomyocytes isolated from neonatal C57 mice, while DCM was stimulated in vivo in db/db mice. Mice and cardiomyocytes were treated with icariin, with or without overexpression or silencing of Apelin and Sirt3 via transfection with adenoviral ve...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
ConclusionsQuality of life in HFpEF is poorest in patients who are young, obese and have diabetes, and is more robustly tied to measures reflecting functional capacity and daily activity levels rather than elevations in NT ‐proBNP or prior HF hospitalization. These findings have major implications for the understanding of QOL in HFpEF and for the design of future clinical trials targeting symptom improvement in HFpEF.Clinical Trial Registration: RELAX, NCT00763867; NEAT ‐HFpEF, NCT02053493; INDIE‐HFpEF, NCT02742129.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
Authors: Verny M, Duyckaerts C Abstract Several disorders are usually involved in the cognitive deficit of the oldest old. Alzheimer disease is the commonest. It is usually characterized by progressive memory impairment - neocortical symptoms occurring much later in the course of the disease. Alzheimer disease should not be considered any more as the single cause of a cognitive deficit in a very old patient. Vascular alterations, possibly causing microinfarcts, are commonly associated, especially in cerebral amyloid angiopathy. A slowly progressive memory deficit with negative CSF biomarkers of Alzheimer's disease ...
Source: Revue Neurologique - Category: Neurology Tags: Rev Neurol (Paris) Source Type: research
More News: Cardiology | Diabetes | Endocrinology | Heart | Heart Failure | Tekturna